Section 4 of 6
Clinical evidence
380 evidence topics · 46 sources
Study summaries
SynAIRgy
Objective
Trial objective as stated in the publication
“To evaluate the efficacy/safety of AD109 over 6 months in a diverse OSA population unable to use PAP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We conducted the phase 3 SynAIRgy clinical trial to evaluate the efficacy, safety, and tolerability of AD109 vs placebo over 6 months in adults with mild-to-severe OSA who were intolerant to or refused PAP therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary and secondary objectives in the design paper
“The primary objective of the LunAIRo and SynAIRgy trials is to demonstrate the efficacy of AD109 versus placebo for upper airway obstruction, as measured by the AHI4, among individuals across the full range of OSA severity, from mild to very severe, over a 26-week treatment period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary objectives are to demonstrate efficacy of AD109 vs placebo on OSA symptoms including fatigue, one of the most common and bothersome OSA symptoms [[13], [14], [15]], and on measures of oxygenation which have been shown to correlate more strongly than AHI with adverse cardiovascular outcomes [16].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory objectives for both trials involve in-depth examination of the effects of AD109 on sleep parameters, and additional measures of airway obstruction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Sites and countries
“conducted at 69 sites in the United States and Canada” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, trial sites were limited to the United States and Canada and may not fully represent OSA in other geographies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of centers, May to October 2025, superseded in May 2026
Registry study dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2023-09-16” |
| Primary completion (actual) | “2025-03-10” |
| Study completion (actual) | “2025-03-14” |
| Enrollment (actual) | “646” |
Registry results posting dates
| Field | Quoted record |
|---|---|
| Results first submitted | “2026-08-18” |
| Results first posted | “2026-09-11” |
Study design
Randomized, double-blind, placebo-controlled parallel-arm design
“SynAIRgy (APC-APN-305; NCT05813275)35 was a phase 3, randomized, double-blind, placebo-controlled, 6-month parallel-arm study of AD109 (Figure S1), conducted at 69 sites in the United States and Canada in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines outlined by the International Council for Harmonisation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible participants were randomized 1:1 to receive AD109 or placebo and stratified according to baseline AHI (<15, 15 to <30, ≥30 events/hour) and PROMIS-Fatigue T-score (<58.5 vs ≥58.5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry design record
| Field | Quoted record |
|---|---|
| Official title | “Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (SynAIRgy Study)” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
Visit schedule and polysomnography timing
“Participants received AD109 or placebo during a 26-week period, including a 1-week run-in dose followed by 25 weeks at the target dose, then 2 weeks without dosing, followed by last visit at week 28 (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Standard overnight polysomnography (PSG) was performed at baseline and weeks 4 and 26.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key patient-reported outcomes (PROs) were assessed using PROMIS-Fatigue and PROMIS-Sleep Impairment 8-item questionnaires at baseline and weeks 4, 13, and 26 (Supplementary Methods).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severity strata enrollment limits
“To ensure representative distribution of baseline AHI4 severity, the size of AHI4 strata will be controlled through enrollment limits, with AHI4 <15 representing ∼20–40% of participants, AHI4 15–30 representing ∼20–40% of participants, and AHI4 >30 representing ∼20–40% of participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding, central polysomnography scoring, and data monitoring
“All study participants, investigators, site staff, staff at the PSG scoring center, staff at the CRO and sponsor staff are blinded to treatment assignment throughout the studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The studies are conducted with the support of a PSG scoring center (Sleep Strategies, Ottawa, ON) responsible for centralized PSG scoring blinded to treatment assignment for both screening and outcome assessment and generation of standardized PSG variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each participant's baseline and on-treatment PSGs were evaluated by the same scorer to maintain consistency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An independent DMC, with expertise in sleep apnea, clinical trials, and biostatistics meets regularly to assess unblinded safety data and make recommendations for both trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Separate sites from the LunAIRo trial
“LunAIRo and SynAIRgy were performed in different centers, with the exception of a small number of sites that enrolled for SynAIRgy after the enrollment of LunAIRo was closed. No participant was enrolled in both studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory cohort of GLP-1 receptor agonist users not analyzed
“An additional exploratory cohort of up to 100 participants receiving a concomitant glucagon-like peptide-1 (GLP-1) receptor agonist specifically for weight loss (ie, not for treatment of type 2 diabetes) was initiated and planned to be analyzed separately to evaluate the potential impact of weight loss on the efficacy and safety of AD109 compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to low enrollment in this cohort, the prespecified exploratory analyses are not included in this report.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Optional open-label extension after completion
Planned randomization and in-treatment polysomnography in the design abstract
Eligibility criteria
Inclusion and exclusion criteria in the publication
“Patients aged ≥18 years with mild-to-severe OSA who had failed or refused PAP therapy were screened for eligibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants with AHI ≥5 events/hour were initially enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An apnea was defined by an event with ≥90% reduction in airflow for ≥10 seconds and hypopnea by ≥30% reduction in airflow for ≥10 seconds associated with a ≥4% decrease in the oxygen saturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The eligibility criterion of enrolling participants with AHI ≥5 events/hour was subsequently changed to ≥10 to ≤45 events/hour to avoid overrepresentation of participants with very severe or very mild OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other inclusion criteria were an 8-item Patient-Reported Outcomes Measurement Information System (PROMIS)–Fatigue T-score >50, representing above-average fatigue and a body mass index (BMI) of 18.5 to 40 kg/m2 in men or 18.5 to 42 kg/m2 in women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key exclusion criteria were clinically significant or medically uncontrolled cardiovascular disease, presence of narcolepsy, restless leg syndrome requiring medication, rapid eye movement (REM) sleep behavior disorder, bothersome symptoms of insomnia, and craniofacial malformation syndromes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry inclusion criteria, current version
Apnea-hypopnea index eligibility range in protocol amendment 5.0, February 2024
Registry exclusion criteria
Definitions of PAP failure and PAP refusal
“PAP failure is defined as no PAP use for ≥3 months prior to randomization, or return/removal of PAP device from the home.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PAP refusal is defined as refusal of PAP after prior positive sleep study, or prior refusal of provider-recommended sleep study due to unwillingness to consider PAP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PROMIS-Fatigue threshold expressed as raw score and T-score
Additional exclusion criteria in the design paper
“Clinically significant or medically uncontrolled cardiovascular disease, or resting heart rate >100), untreated or unstable coronary artery disease, heart failure, cerebrovascular event or revascularization within 3 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Schizophrenia, schizoaffective disorder, generalized anxiety disorder or bipolar disorder according to DSM-5 criteria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attempted suicide within 1 year prior to screening, or current suicidal ideation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blood pressure >145/90 mmHg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Narrow angle glaucoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Women who are pregnant or nursing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disallowed concomitant medications
“Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strong CYP2D6 inhibitors, and strong CYP3A4 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Modafinil, armodafinil, solriamfetol, and pitolisant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral anticholinergics, and cholinesterase inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drugs used exclusively for weight loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Apnea-hypopnea index eligibility in protocol versions 2.0 and 4.0, July 2023, superseded in February 2024
Apnea-hypopnea index eligibility in congress abstracts, April 2024 and May 2025, superseded in May 2026
Treatment
AD109 regimen with one-week run-in and no dose reduction
Registry intervention descriptions
Dispensing and dosing rules
“The IMP is dispensed as a blister package of 7 run-in dose tablets and a bottle containing 33 target dose tablets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose reduction is not permitted, and dosing is discontinued if the participant experiences intolerance to the assigned study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants are not prohibited from initiating PAP during the trial if deemed by the participant's primary care provider to be in the participant's best medical interest.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Run-in dose in base notation and reason dose reduction was not permitted
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Primary endpoint: change in AHI with 4% desaturation hypopnea rule at week 26
Key secondary and exploratory endpoints
“The key secondary efficacy endpoints (at week 26) were change from baseline in oxygen desaturation index based on 3% desaturation (ODI), PROMIS-Fatigue T-score, hypoxic burden based on 4% desaturation (HB), PROMIS-Sleep Impairment T-score, and proportion of participants with ≥50% reduction in AHI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prespecified exploratory endpoints (at week 26) included change from baseline in OSA severity category (none [AHI <5], mild [AHI 5 to <15], moderate [AHI 15 to <30], and severe [AHI ≥30]), proportion of participants with AHI reduction of ≥30% to ≥90% by 10% increments, and proportion of breaths with snoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other secondary endpoints in the design paper
“Other secondary endpoints in both trials include the change from baseline in the PGI-S score for fatigue at Week 26, the patient global impression of change (PGI-C) score for fatigue at Week 26, and the change from baseline in ESS at Week 26.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for AHI, oxygen desaturation index, and hypoxic burden
“The primary efficacy endpoint in most OSA trials is the AHI which historically has been the principal biomarker for the disease [[22], [23], [24], [25]].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to AHI4, that only considers the frequency of obstructive events (events/hour of sleep), the HB4 also incorporates the length and the depth of the apnea/hypopnea-related chronic intermittent hypoxia during sleep [16].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This metric has demonstrated a stronger correlation with cardiovascular mortality than AHI in recent epidemiological cohort analyses [16].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for PROMIS-Fatigue as a key secondary endpoint
“Fatigue is one of the most common and most bothersome symptoms of OSA and is a distinct symptom from sleepiness [13].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PROMIS-Fatigue may provide increased sensitivity to symptom improvement in OSA [31], particularly in the substantial proportion of OSA patients without EDS [32].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Content validity and meaningful change of the patient-reported outcome measures, SynAIRgy exit interviews
“Qualitative exit interviews were conducted with 32 participants within 10 days of completing the trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mapping demonstrated all PROMs have strong concept coverage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most participants reported a one-point change on response options for individual items from the PROMIS-Fatigue (61%-96%), PROMIS-Sleep Impairment (52%-96%), and ESS (62-96%) was clinically meaningful, regardless of baseline response.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A one-point change on PROMs represents a clinically meaningful improvement from the patient's perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Investigators' rationale for the clinical meaningfulness of the AHI change, treatment policy and on-treatment estimands
“At the group level, treatment was associated with a shift in disease severity from the moderate to mild range (from a median of 19.8 at baseline to 13.3 at week 26 in the ITT, and from a median of 19.3 at baseline to 10.6 at week 26 in the on-treatment estimand).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This magnitude of improvement, we believe, is clinically meaningful, as mild OSA has been associated with lower cardiovascular, metabolic, and neurocognitive risk compared to moderate OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 26 weeks, >25% of participants in the AD109 arm achieved ≥50% reduction in AHI, a clinically meaningful improvement based on American Academy of Sleep Medicine guidelines,45,46 although this effect was not statistically significant compared with the placebo arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company position on relative rather than absolute AHI change in mild and moderate disease
FDA pre-NDA feedback on the clinical meaningfulness of the primary endpoint results
Editorial comment on the clinical significance of the absolute AHI change, treatment policy estimand
Protocol amendment 6.0 reordering the primary and key secondary endpoints, April 2025
Primary endpoint: responder proportion in protocol version 4.0, December 2023, superseded in April 2025
Primary endpoint: responder proportion in the registry record, March 2025, superseded in November 2025
Primary endpoint: responder proportion in congress abstracts, April 2024 and May 2025, superseded in May 2025
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power
“The sample size (640 participants) was calculated based on the number of participants required to provide >90% power for the primary endpoint and one of the key secondary efficacy endpoints (change from baseline to week 26 in PROMIS-Fatigue T-score) at a 2-sided significance level of 0.05 (Supplementary Methods).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sample size assumptions from the MARIPOSA trial
“In a previous Phase 2 study (MARIPOSA), the standard deviation of the placebo group change from baseline in AHI4 was approximately 9.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the observed dropout rates in MARIPOSA, it is assumed that the dropout rate in the placebo group will be 5% and the dropout rate in the AD109 group will be 25%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 640 participants (320/group) will provide >98% power to detect a treatment difference of ≥ 4 points between AD109 and placebo for the change in AHI4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With these assumptions, simulation demonstrated that 640 participants (320/group) would provide approximately 90% power to detect a treatment difference of 2.5 points and approximately 95% power to detect a treatment difference of 2.75 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants randomized and analyzed
Participants excluded from the efficacy analyses
“The 7 participants (5 in the AD109 arm and 2 in the placebo arm) randomized and treated in the exploratory cohort are included in the safety analysis but not in the efficacy analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen participants enrolled at site 1416 in the AD106 arm were excluded from the efficacy analyses because the site was terminated due to Good Clinical Practice noncompliance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Six participants enrolled at site 1416 in the placebo arm were excluded from the efficacy analyses because the site was terminated due to Good Clinical Practice noncompliance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These numbers reflect participants by assigned treatment, but 2 participants who were assigned to placebo received AD109 instead.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Treatment policy estimand (intent-to-treat) and on-treatment estimand
“Primary analyses of the efficacy endpoints were performed using an intent-to-treat approach (ITT); supportive analyses were performed using the on-treatment estimand.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ITT analysis included all randomized participants who received ≥1 dose of AD109/placebo and evaluated endpoints regardless of treatment adherence or discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the ITT estimand, missing data were assumed to be missing-not-at-random, and endpoints were analyzed with a pattern-mixture model using a jump-to-reference approach by means of sequential modeling with multiple imputation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The on-treatment estimand included all randomized participants who received ≥1 dose of AD109/placebo and who had ≥1 post-baseline PSG assessment on treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The on-treatment estimand focused on endpoints observed during active treatment exposure and excluded data collected after treatment discontinuation, with missing values imputed using a last observation carried forward approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry definitions of the Primary Full Analysis Set and While-on-Treatment population
Statistical model and responder analysis
“The primary analysis for the primary and secondary endpoints defined on a continuous scale used a restricted maximum likelihood–based mixed model for repeated measurements in combination with the Newton–Raphson algorithm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of the proportion of participants with ≥50% reduction in AHI at week 26 (key secondary endpoint not on a continuous scale) was conducted using the stratified Cochran–Mantel–Haenszel procedure, and estimates of risk difference between arms, along with the 2-sided 95% CI, were calculated based on the Cochran–Mantel–Haenszel stratum weights38 and the Sato variance estimator.39” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the proportion of participants with ≥50% reduction in AHI, participants who discontinued treatment were considered nonresponders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiplicity control and hierarchical testing order
“For the primary endpoint, no adjustment for multiplicity was needed and a 2-sided 5% significance level was used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjustment for multiplicity of the key secondary endpoints was conducted through a closed testing approach, where each key secondary endpoint was tested in a prespecified order: (1) change from baseline to week 26 in ODI, (2) change from baseline to week 26 in PROMIS-Fatigue T-score, (3) change from baseline to week 26 in HB, (4) change from baseline to week 26 in PROMIS-Sleep Impairment T-score, and (5) proportion of participants with ≥50% reduction in AHI at week 26.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key secondary endpoints that are nominally statistically significant but occur after a nonsignificant result in the prespecified hierarchical testing sequence should be interpreted with caution, as formal statistical significance cannot be claimed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relative change in AHI on the log scale added as an exploratory analysis in statistical analysis plan version 2.0, April 2025
Per-protocol population as described by the company
Results
Participant disposition
Trial completion and completion of six months of treatment
“Among participants who received treatment, 84.6% (539/637) completed the trial, with 83.3% (265/318) in the AD109 group and 85.9% (274/319) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 74.7% (476/637) completed 6 months of treatment (65.7% [209/318] with AD109 and 83.7% [267/319] with placebo; Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment adherence
“In the AD109 arm, treatment adherence (percent compliant) was 95.7% (SD, 9.2%) for participants completing the study on treatment, and 90.2% (SD, 35.2%) for those discontinuing treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the placebo arm, treatment adherence was 95.5% (SD, 9.5%) for participants completing the study on treatment, and 77.5% (SD, 42.4%) for those discontinuing treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall treatment discontinuation before week 26
Timing of treatment discontinuation
“AE-related discontinuations occurred predominantly early after treatment initiation, with markedly fewer events later in the treatment period (Figure S10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, non-AE-related discontinuations were similar between the AD109 and placebo arms and were distributed more uniformly over time and generally at lower counts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry participant flow and reasons for study withdrawal
Main cohort completion in the congress abstract
Baseline characteristics
Baseline characteristics, intent-to-treat set, AHI with 4% desaturation hypopnea rule
Distribution of baseline severity and body mass index in the intent-to-treat set
“The distribution of baseline OSA severity was broad and right-skewed with 34.8% (214/615) mild, 42.1% (259/615) moderate, and 23.1% (142/615) severe (Table 1, Figure S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline insomnia was assessed based on participant-reported medical history obtained at screening and includes initial insomnia (difficulty falling asleep at the beginning of the night), insomnia, and middle insomnia (difficulty maintaining sleep, characterized by frequent or prolonged nighttime awakenings).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry baseline age and mean AHI with 4% desaturation hypopnea rule, Primary Full Analysis Set
| Characteristic | AD109 | Placebo | Total |
|---|---|---|---|
| Age, years, mean (SD) | “57.5(10.67)” | “57.1(11.11)” | “57.3(10.89)” |
| Baseline AHI4, events/hr, mean (SD) | “22.13(11.819)” | “21.47(10.607)” | “21.79(11.214)” |
Baseline characteristics, all 646 randomized participants, AHI with 4% desaturation hypopnea rule
Baseline oxygenation measures, all 646 randomized participants
| Characteristic | Quoted value |
|---|---|
| ODI3, mean (SD) | “29 (13)”View highlighted excerpt for this quote |
| HB4, mean (SD) | “43 (40)”View highlighted excerpt for this quote |
Efficacy results
Primary and key secondary endpoints at week 26, treatment policy estimand, AHI with 4% desaturation hypopnea rule
Relative reduction in AHI with 4% desaturation hypopnea rule at week 26, treatment policy estimand
“These changes represent a model-estimated 44.1% geometric mean reduction in AHI from baseline to week 26 in the AD109 arm vs 17.6% reduction in the placebo arm (P <.0001; Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median (95% CI) AHI was reduced from 19.8 (18.3-21.2) in the moderate severity range at baseline to 13.3 (10.7-15.9) in the mild severity range at week 26 with AD109, and from 19.1 (17.0-20.2) at baseline to 17.7 (15.3-20.8) at week 26 with placebo (Figure 2B; Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 4 placebo-adjusted AHI change and responder difference, treatment policy estimand
“The placebo-adjusted reduction at week 4 was −5.7 (−7.5 to −3.8); P <.0001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment difference at week 4 was 21.7 (14.8-28.5); P <.0001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry primary endpoint result for change in AHI with 4% desaturation hypopnea rule at 6 months, treatment policy and while-on-treatment estimands
Primary and key secondary endpoints at week 26, on-treatment estimand, AHI with 4% desaturation hypopnea rule
Relative and median AHI with 4% desaturation hypopnea rule at week 26, on-treatment estimand
Week 4 placebo-adjusted AHI change and responder difference, on-treatment estimand
“The placebo-adjusted reduction at week 4 was −6.7 (−8.7 to −4.8); P <.0001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment difference at week 4 was 27.1 (19.7-34.4); P <.0001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relative AHI reduction by estimand as reported by the company
Topline primary endpoint result and relative AHI reduction, as reported in the company release
Responders with at least 50% AHI reduction at weeks 4 and 26, treatment policy and on-treatment estimands
“Clinically meaningful response was observed as early as week 4 based on the ≥50% reduction in AHI responder rates, suggesting that the lower treatment difference at week 26 could be attributed to the higher early treatment discontinuation rate with AD109 relative to placebo, since participants who discontinued treatment were classified as nonresponders in this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severity category improvement and disease control at week 26, treatment policy estimand
“AD109 improved OSA disease severity category in 41.8% of participants (vs 33.6% for placebo), with 17.6% achieving complete OSA disease control (AHI <5) at week 26 vs 9.3% for placebo (P = .012; Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reductions ≥70% in AHI at week 26 were reported in 17.2% (52/302) of the AD109 arm vs 8.9% (28/313) in the placebo arm (P = .003; Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severity category improvement and disease control at week 26, on-treatment estimand
Oxygen desaturation index with 3% desaturation criterion, relative change by estimand
Oxygen desaturation index and hypoxic burden, on-treatment estimand, as reported in the CHEST 2025 company release
Hypoxic burden with 4% desaturation criterion outside formal hierarchical testing, treatment policy estimand
“Based on the prespecified hierarchical testing approach for secondary endpoints, formal endpoint testing ended before analysis of HB.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The geometric mean percent reduction in HB at week 26 was 44.7% for participants in the AD109 arm vs 8.5% for participants in the placebo arm (nominal P <.0001; Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-REM, REM, and supine AHI with 4% desaturation hypopnea rule at week 26, on-treatment estimand
Apnea index and hypopnea index at week 26, on-treatment estimand
Arousal indexes at week 26, on-treatment estimand
| Measure | AD109 change, median (IQR) | Placebo change, median (IQR) |
|---|---|---|
| Respiratory arousal index, events/h | “0.1 (−5.0 to 5.8)”View highlighted excerpt for this quote | “1.3 (−3.5 to 7.5)”View highlighted excerpt for this quote |
| Total arousal index, events/h | “2.9 (−2.5 to 10.5)”View highlighted excerpt for this quote | “1.6 (−3.9 to 8.7)”View highlighted excerpt for this quote |
Subgroups and adjustment for REM sleep and body mass index, treatment policy and on-treatment estimands
“Similar improvements in AHI at week 26 were observed among participants in the AD109 arm across various subgroups including sex, baseline OSA severity categories (mild, moderate, and severe), and BMI classes (Figure S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AD109 treatment effects on AHI were consistent across estimands, with larger effect sizes observed in the supportive on-treatment estimand in participants who tolerated treatment (Table 3, Figure 2D and E, Figure S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The evaluation of the treatment effect on AHI and HB at week 26 performed with an adjusted model including the change from baseline in proportion of REM sleep and BMI is provided in Table S3 and shows that the reduction in AHI is independent from reduction in REM and BMI in the treatment arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
PROMIS-Fatigue at week 26, treatment policy and on-treatment estimands
“AD109 reduced PROMIS-Fatigue T-scores at week 26 by a mean of 7.4 points compared with 6.2 points in the control arm, such that the difference between arms did not meet statistical significance (P = .059; Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the supportive on-treatment estimand analyses, PROMIS-Fatigue T-scores fell at week 26 by 7.5 points with AD109 vs 6.2 points with placebo (P = .030; Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PROMIS-Fatigue by baseline fatigue and daytime sleepiness, treatment policy estimand
PROMIS-Sleep Impairment at week 26, treatment policy estimand
“The PROMIS-Sleep Impairment T-score improved by 7.6 points in the AD109 arm but the improvement in the placebo arm was similar, such that no treatment effect was observed between arms (P = .316; Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PROMIS-Fatigue and PROMIS-Sleep Impairment at week 26, on-treatment estimand, congress abstract
Placebo response in patient-reported outcomes
“The substantial improvement in symptoms observed in both arms suggests that the placebo effect may have impaired the ability to detect true clinical improvements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the context of PRO assessments, participants were never specifically asked if they were aware of receiving placebo, so we cannot rule out the possibility of expectation bias influencing responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Editorial comment on patient-reported outcomes
Epworth Sleepiness Scale and patient global impression endpoints
No evidence found.
Safety results
Overall safety summary, safety analysis set
Treatment discontinuation due to adverse events
“Overall, 21.2% (69/325) of participants receiving AD109 and 3.1% (10/319) of participants receiving placebo discontinued treatment due to an AE (Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary (occurring in ≥7 participants) AEs leading to AD109 discontinuation were insomnia, urinary hesitation, and nausea (Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events leading to treatment discontinuation in two or more participants
| Event | AD109 (n = 325), n (%) |
|---|---|
| Insomnia | “16 (4.9)”View highlighted excerpt for this quote |
| Urinary hesitation | “8 (2.5)”View highlighted excerpt for this quote |
| Nausea | “7 (2.2)”View highlighted excerpt for this quote |
| Erectile dysfunction or sexual dysfunction | “5 (1.5)”View highlighted excerpt for this quote |
| Dry mouth | “4 (1.2)”View highlighted excerpt for this quote |
| Hypertension | “3 (0.9)”View highlighted excerpt for this quote |
| Palpitations | “3 (0.9)”View highlighted excerpt for this quote |
| Upper abdominal pain | “2 (0.6)”View highlighted excerpt for this quote |
| Feeling jittery | “2 (0.6)”View highlighted excerpt for this quote |
| Urinary retention | “2 (0.6)”View highlighted excerpt for this quote |
Severity of adverse events and serious adverse events
“The most common AEs were generally mild in severity (Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serious AEs were reported by 1.5% (5/325) of participants who received AD109 and 2.5% (8/319) of participants who received placebo; all were deemed by investigators to be unrelated to study medication (Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the AD109 arm, 5 participants experienced the following serious adverse events (all unrelated to AD109 treatment): 1 participant had cholelithiasis and cholestatic hepatitis, 1 participant had gastritis and bacterial pneumonia, 1 participant had asthma and chronic obstructive pulmonary disease, 1 participant had cholecystitis, and 1 participant had malignant melanoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No deaths were reported in the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry adverse events at the 5% reporting threshold, safety population
| Event | AD109, affected/at risk (%) | Placebo, affected/at risk (%) |
|---|---|---|
| Serious adverse events, total | “5/325 (1.54%)” | “8/319 (2.51%)” |
| Other adverse events, total | “176/325 (54.15%)” | “50/319 (15.67%)” |
| Dry mouth | “115/325 (35.38%)” | “29/319 (9.09%)” |
| Nausea | “37/325 (11.38%)” | “2/319 (0.63%)” |
| Constipation | “17/325 (5.23%)” | “4/319 (1.25%)” |
| Somnolence | “17/325 (5.23%)” | “10/319 (3.13%)” |
| Middle insomnia | “38/325 (11.69%)” | “10/319 (3.13%)” |
| Initial insomnia | “30/325 (9.23%)” | “4/319 (1.25%)” |
| Urinary hesitation | “29/325 (8.92%)” | “1/319 (0.31%)” |
Any adverse event counts in the congress abstract
Heart rate and blood pressure, safety analysis set
| Measure | AD109, mean change (SD) [n] | Placebo, mean change (SD) [n] |
|---|---|---|
| Heart rate, beats/min, baseline day 1 to week 26 day 1 | “1.5 (9.8) [268]”View highlighted excerpt for this quote | “−1.9 (10.1) [277]”View highlighted excerpt for this quote |
| Heart rate, beats/min, baseline day 2 to week 26 day 2 | “3.6 (9.4) [267]”View highlighted excerpt for this quote | “0.0 (9.2) [276]”View highlighted excerpt for this quote |
| Systolic blood pressure, mm Hg, baseline day 1 to week 26 day 1 | “1.4 (11.8) [268]”View highlighted excerpt for this quote | “1.7 (11.9) [277]”View highlighted excerpt for this quote |
| Diastolic blood pressure, mm Hg, baseline day 1 to week 26 day 1 | “0.9 (8.0) [268]”View highlighted excerpt for this quote | “−0.5 (7.7) [277]”View highlighted excerpt for this quote |
Heart rate of 100 beats per minute or higher at any time on treatment
“Changes in blood pressure and heart rate were small, although a small subgroup of participants showed tachycardia while on AD109.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Measure | AD109 (n = 325), n (%) | Placebo (n = 319), n (%) | P value |
|---|---|---|---|
| Heart rate ≥100 beats/min, on study | “20 (6.3)”View highlighted excerpt for this quote | “6 (1.9)”View highlighted excerpt for this quote | “.006”View highlighted excerpt for this quote |
| Systolic blood pressure ≥140 mm Hg, on study | “83 (26.3)”View highlighted excerpt for this quote | “82 (26.5)”View highlighted excerpt for this quote | “.939”View highlighted excerpt for this quote |
| Diastolic blood pressure ≥90 mm Hg, on study | “65 (20.6)”View highlighted excerpt for this quote | “64 (20.7)”View highlighted excerpt for this quote | “.956”View highlighted excerpt for this quote |
Sleep architecture at week 26, post hoc analysis in the safety analysis set
Insomnia as a reason for discontinuation and baseline insomnia assessment
“The population studied must have been intolerant to or refused PAP therapy to enroll; thus, the trial may have been enriched with participants who may have exhibited some degree of subclinical insomnia.41 However, insomnia was not assessed in a standardized manner in this trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Editorial comment on tolerability and long-term safety
Study limitations
Summary
- Design: 26 weeks of treatment against placebo, with polysomnography at baseline and weeks 4 and 26; no active comparator. Dose reduction was not permitted, and participants could start PAP during the trial.
- Population: adults intolerant of or refusing PAP, with a PROMIS-Fatigue T-score above 50 and a BMI cap of 40 (men) or 42 (women) kg/m2. Exclusions included clinically significant cardiovascular disease, blood pressure above 145/90 mmHg, bothersome insomnia, specified psychiatric disorders, and narrow angle glaucoma. Sites were limited to the United States and Canada, which the authors state may not represent OSA in other geographies.
- Eligibility AHI changed during enrollment: protocol version 2.0 (July 2023) required more than 5 to 45 events/h, version 5.0 (February 2024) required 10 to 45, and the publication states participants with AHI of 5 or more were enrolled first. The 2024 congress abstract described AHI4 of 5 or more, and the 2025 abstract AHI4 above 5 with no upper limit. Enrollment ran from December 20, 2023 to March 26, 2025.
- Severity mix: enrollment limits capped each AHI4 stratum at about 20% to 40%, and the authors state the population skewed toward mild-to-moderate disease, which can limit absolute effects; the editorial gives a median baseline AHI of 19.6.
- Endpoint change: protocol version 4.0 (December 2023) named the proportion with at least 50% AHI reduction as the primary endpoint. Amendment 6.0 (17 April 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”. The registry version of 2025-03-18 named the proportion of participants with reduction in AHI as the primary outcome, and the next version, submitted 2025-11-18, changed the outcome measures. The amendment postdates the registry's actual primary completion date (2025-03-10). Statistical analysis plan version 2.0 (22 April 2025) added the relative change in AHI on the log scale as an exploratory analysis.
- Estimands and missing data: the primary treatment policy analysis assumed data missing not at random (jump-to-reference multiple imputation). The supportive on-treatment estimand excluded data collected after treatment discontinuation and imputed missing values by last observation carried forward; it included 260 participants on AD109 and 296 on placebo, against 302 and 313 in the treatment policy set. The topline release reported the on-treatment relative reduction (55.6%) beside the treatment policy primary result (p=0.001).
- Analysis-set exclusions: 22 participants (16 AD109, 6 placebo) at site 1416, terminated for Good Clinical Practice noncompliance, and 7 participants in the exploratory GLP-1 receptor agonist cohort were excluded from efficacy analyses; that cohort's analyses were not reported because of low enrollment.
- Discontinuation: treatment discontinuation before 26 weeks was 34.3% with AD109 and 16.3% with placebo in the publication, which the authors state likely diminished the observed benefit; the prospectus reports 34.6% and 16.5% at month 6 in the main cohort. Treatment discontinuation due to adverse events was 21.2% and 3.1%; study withdrawal due to adverse events in the registry was 4 and 1 participants.
- Hierarchical testing: under the treatment policy estimand, PROMIS-Fatigue (P = .059) did not reach significance, so formal testing ended before hypoxic burden, and the responder endpoint was not significant (P = .182).
- Patient-reported outcomes: the authors cite a placebo response in both arms and possible expectation bias, and state insomnia was not assessed in a standardized manner although the PAP-intolerant population may have been enriched for subclinical insomnia.
- Clinical meaningfulness: at the pre-NDA meeting the FDA gave feedback on the clinical meaningfulness of the primary endpoint results and the limitations of the PROs, and indicated additional analyses and justification may be needed. The editorial states the clinical significance of the placebo-adjusted reduction of about 4 events per hour is uncertain as a continuous measure, and that durability, long-term safety, and effects on cardiovascular events require further study.
- Sponsor: the prospectus describes SynAIRgy as a trial the company conducted.
LunAIRo
Objective
Primary and secondary objectives in the design paper
“The primary objective of the LunAIRo and SynAIRgy trials is to demonstrate the efficacy of AD109 versus placebo for upper airway obstruction, as measured by the AHI4, among individuals across the full range of OSA severity, from mild to very severe, over a 26-week treatment period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additional objectives for the LunAIRo trial include exploring both long-term efficacy and safety endpoints over a 51-week placebo-controlled period, and exploring time points as early as 4 weeks to evaluate rapid onset of efficacy of AD109.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study rationale and purpose in the protocol
Location and study date
Study dates in the ClinicalTrials.gov record
“Study Start (Actual) 2023-08-28” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-05-07” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-05-07” (opens the source at this quote in a new tab)
“Results First Posted 2026-11-03” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Sites in the United States
“A total of 64 sites have been identified in the U.S. for LunAIRo (Supplemental Table 1) and 73 sites have been identified in both the U.S. and Canada for SynAIRgy (Supplemental Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LunAIRo and SynAIRgy were performed in different centers, with the exception of a small number of sites that enrolled for SynAIRgy after the enrollment of LunAIRo was closed. No participant was enrolled in both studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial initiation and completion in the prospectus
Study design
Design, randomization, and duration in the protocol
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Official title | “Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (LunAIRo Study)” |
| Other study ID | “APC-APN-304” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Enrollment | “Enrollment (Actual) 660” |
Stratified randomization and severity strata
“Randomization is stratified according to baseline AHI4 (<15, 15 to 30, >30) and 8-item PROMIS-Fatigue raw score (<25 vs ≥ 25; a raw score of 25 is equivalent to a T-score of 58.5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To ensure representative distribution of baseline AHI4 severity, the size of AHI4 strata will be controlled through enrollment limits, with AHI4 <15 representing ∼20–40% of participants, AHI4 15–30 representing ∼20–40% of participants, and AHI4 >30 representing ∼20–40% of participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Polysomnography schedule and central scoring
“Objective efficacy data are gathered with in-laboratory polysomnograms (PSG) performed at 13, 26, and 51 weeks for the LunAIRo study, and at 4 and 26 weeks for the SynAIRgy study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The studies are conducted with the support of a PSG scoring center (Sleep Strategies, Ottawa, ON) responsible for centralized PSG scoring blinded to treatment assignment for both screening and outcome assessment and generation of standardized PSG variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each participant's baseline and on-treatment PSGs were evaluated by the same scorer to maintain consistency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ambulatory blood pressure monitoring and blinding
“Eligible participants in the LunAIRo trial, after V2, will be encouraged to undergo optional 24 h ambulatory blood pressure monitoring (ABPM) before the randomization visit (V3). The ABPM procedure is repeated after 4 weeks of treatment with AD109 or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All study participants, investigators, site staff, staff at the PSG scoring center, staff at the CRO and sponsor staff are blinded to treatment assignment throughout the studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An independent DMC, with expertise in sleep apnea, clinical trials, and biostatistics meets regularly to assess unblinded safety data and make recommendations for both trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension after the trial
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
Apnea-hypopnea index range and PAP criteria in protocol version 4.0
Apnea-hypopnea index range in the baseline abstract
“Since the mechanism of action should apply, in theory, to all OSA patients, no limit to OSA severity is implemented initially, however caps could be implemented during the trial to ensure that the full range of OSA severities are well-represented in the trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key exclusion criteria and fatigue threshold in the design paper
“Current bothersome symptoms of insomnia (difficulty initiating or maintaining sleep, as distinct from unrefreshing sleep or other symptoms attributable to OSA). Participants treated with insomnia can be enrolled if symptoms are controlled” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Schizophrenia, schizoaffective disorder, generalized anxiety disorder or bipolar disorder according to DSM-5 criteria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attempted suicide within 1 year prior to screening, or current suicidal ideation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blood pressure >145/90 mmHg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Narrow angle glaucoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only participants who refuse or are intolerant to PAP and with a raw PROMIS-Fatigue score ≥17 (fatigue level above average of the population; a raw score of 17 is equivalent to a T-score of 50.4) are eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disallowed concomitant medications
“Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MAOIs, NRIs, and TCAs,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strong CYP2D6 inhibitors, and strong CYP3A4 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drugs used exclusively for weight loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Modafinil, armodafinil, solriamfetol, and pitolisant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral anticholinergics, and cholinesterase inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Treatment arms in the ClinicalTrials.gov record
No dose reduction, and continued follow-up after discontinuation
PAP initiation permitted during the trial
“Participants are not prohibited from initiating PAP during the trial if deemed by the participant's primary care provider to be in the participant's best medical interest. Dosing of AD109 or placebo can continue if PAP is initiated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Primary endpoint: change from baseline in AHI4 at week 26
Protocol amendment 4.0: reordering of the primary and key secondary endpoints, June 2025
Primary endpoint: proportion with at least 50% reduction in AHI4 at six months in the baseline abstract, May 2025, superseded in June 2025
Key secondary and secondary endpoints, in the order tested
Apnea-hypopnea index as the historical principal biomarker, and hypoxic burden as a complementary metric
“The primary efficacy endpoint in most OSA trials is the AHI which historically has been the principal biomarker for the disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to AHI4, that only considers the frequency of obstructive events (events/hour of sleep), the HB4 also incorporates the length and the depth of the apnea/hypopnea-related chronic intermittent hypoxia during sleep [16]. This metric has demonstrated a stronger correlation with cardiovascular mortality than AHI in recent epidemiological cohort analyses [16].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PROMIS-Fatigue as a key secondary endpoint
“Fatigue is one of the most common patient-reported symptoms in relationship to sleep apnea and disturbed sleep, together with sleepiness [18].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PROMIS-Fatigue may provide increased sensitivity to symptom improvement in OSA [31], particularly in the substantial proportion of OSA patients without EDS [32].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company interpretation of absolute and relative AHI reductions in a mostly mild-to-moderate population
FDA pre-NDA feedback on the clinical meaningfulness of the primary endpoint results and the limits of the patient-reported outcomes
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power
“A total of 640 participants (320/group) will provide >98% power to detect a treatment difference of ≥ 4 points between AD109 and placebo for the change in AHI4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the observed dropout rates in MARIPOSA, it is assumed that the dropout rate in the placebo group will be 5% and the dropout rate in the AD109 group will be 25%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With these assumptions, simulation demonstrated that 640 participants (320/group) would provide approximately 90% power to detect a treatment difference of 2.5 points and approximately 95% power to detect a treatment difference of 2.75 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants analyzed for the primary endpoint, by estimand
Description of analysis sets
Analysis sets in the statistical analysis plan
Analysis populations in the ClinicalTrials.gov record
Treatment policy estimand for the primary endpoint
While-on-treatment estimand as a supportive analysis
Statistical model for the primary endpoint
“The primary analysis methodology will utilize a restricted maximum likelihood (REML) based mixed model for repeated measurements (MMRM) in combination with the Newton Raphson Algorithm. Analyses will include treatment, AHI4 strata, time and the treatment by time interaction as a fixed effects and baseline score as a covariate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of participants with ≥50% reduction in AHI4 at Week 26 will be compared between treatment groups using the stratified Cochran-Mantel Haenszel procedure, controlling for randomization strata.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiplicity control for the key secondary endpoints
Week 51 endpoints analyzed as tertiary endpoints
Pooled phase 3 analysis: estimands and analysis sets
Results
Participant disposition
Treatment discontinuation due to adverse events and overall treatment discontinuation by month 6 and month 12
Pooled phase 3 analysis: study completion and overall treatment discontinuation by week 26
Pooled phase 3 analysis: treatment discontinuation due to adverse events by week 26
Baseline characteristics
Baseline characteristics in the design paper
Baseline characteristics of the full analysis set in the ClinicalTrials.gov record
| Characteristic | AD109 (n = 324) | Placebo (n = 326) |
|---|---|---|
| Age, years, mean (SD) | “57.2(10.26)” | “57.4(10.72)” |
| Female | “160” | “138” |
| Male | “164” | “188” |
| Black or African American | “58” | “53” |
| White | “238” | “246” |
| Baseline AHI4 below 15 | “119” | “125” |
| Baseline AHI4 15 to 30 | “109” | “104” |
| Baseline AHI4 above 30 | “96” | “97” |
| Baseline AHI4, events/hr, mean (SD) | “24.03(16.692)” | “24.69(18.735)” |
Demographics, AHI4 severity, and symptoms in the baseline abstract
Median baseline AHI4 in the on-treatment set
Pooled phase 3 analysis: baseline severity and AHI distribution
Efficacy results
Week 26 change from baseline in AHI4, treatment policy and while-on-treatment estimands, in the ClinicalTrials.gov record
| Comparison | LS mean difference | Lower 95% CI | Upper 95% CI | p-value |
|---|---|---|---|---|
| “Analyses were conducted under the Treatment Policy estimand” | “-4.08” | “-6.14” | “-2.03” | “<0.001” |
| “Analyses were conducted under the While-on-Treatment Estimand” | “-5.81” | “-8.07” | “-3.55” | “<0.0001” |
Week 26 change in AHI4, treatment policy estimand (ITT set)
Week 26 relative change in AHI4, treatment policy and on-treatment estimands
Week 26 and week 51 change in AHI4, on-treatment estimand (mITT set)
Week 26 and week 51 AHI reduction as reported in the company release
Attenuation of the treatment policy estimate at week 51
Key secondary endpoint: week 26 ODI3, on-treatment estimand (mITT set)
Key secondary endpoint: week 26 ODI3, treatment policy and on-treatment estimands
Key secondary endpoint: week 26 hypoxic burden, treatment policy and on-treatment estimands
Key secondary endpoint: at least 50% reduction in AHI4 at week 26, on-treatment estimand (mITT set)
Key secondary endpoint: at least 50% reduction in AHI at week 26, treatment policy and on-treatment estimands
Severity category improvement and disease control at week 26, on-treatment estimand (mITT set)
Severity category improvement and disease control at weeks 26 and 51, as reported in the company release
Apnea index and hypopnea index at week 26, estimand not stated
Pooled phase 3 analysis: week 26 change in AHI4, treatment policy estimand
Pooled phase 3 analysis: week 26 change in AHI4, on-treatment estimand
Pooled phase 3 analysis: responders, disease control, and hypoxic burden, treatment policy estimand
Pooled phase 3 analysis: responders, disease control, and hypoxic burden, reported after the on-treatment estimand results
Pooled phase 3 analysis: severity category improvement and disease control, treatment policy and on-treatment estimands
Pooled phase 3 analysis: week 26 AHI adjusted for changes in REM sleep and BMI, on-treatment estimand
| Model, LS mean (95% CI), events/h at week 26 | AD109 (n = 500) | Placebo (n = 589) | Estimated treatment difference (95% CI) | p-value |
|---|---|---|---|---|
| Primary model for change from baseline in AHI | “–6.1 (–7.3 to –4.9)” | “0.1 (–1.0 to 1.2)” | “–6.2 (–7.8 to –4.6)” | “<0.0001” |
| Model adjusted for change in proportion of REM sleep | “–5.7 (–7.1 to –4.2)” | “0.2 (–1.1 to 1.4)” | “–5.9 (–7.9 to –3.8)” | “<0.0001” |
| Model adjusted for change in BMI | “–5.1 (–6.4 to -3.8)” | “–0.2 (–1.4 to 0.9)” | “–4.9 (–6.6 to –3.1)” | “<0.0001” |
Pooled phase 3 analysis: snoring frequency at week 26 in participants with an on-treatment polysomnogram
Pooled phase 3 analysis: modeled cardiovascular risk reduction from hypoxic burden, treatment policy and on-treatment estimands
Pooled phase 3 analysis: AHI response with concomitant GLP-1 receptor agonists, estimand not stated
Pooled phase 3 analysis: body weight change with concomitant GLP-1 receptor agonists for diabetes, exploratory, estimand not stated
Health-related quality of life and patient-reported outcomes
Key secondary endpoint: week 26 PROMIS-Fatigue T-score, on-treatment estimand (mITT set)
Week 26 PROMIS-Fatigue and PROMIS-Sleep Impairment, treatment policy and on-treatment estimands
Pooled phase 3 analysis: week 26 PROMIS-Fatigue, PROMIS-Sleep Impairment, and ESS, on-treatment estimand
Pooled phase 3 analysis: participants with baseline ESS of 10 or more, on-treatment estimand
Pooled phase 3 analysis: participants with baseline ESS of 10 or more, treatment policy estimand
Pooled phase 3 analysis: per-protocol set, treatment policy estimand dataset
Pooled phase 3 analysis: association between baseline AHI and baseline patient-reported outcomes
Safety results
Overall adverse events and most common adverse events
Adverse event reporting period and definition
Non-serious adverse events in at least 5% of participants in either arm
| Adverse event | AD109, affected / at risk (%) | Placebo, affected / at risk (%) |
|---|---|---|
| Total | “220/328 (67.07%)” | “122/327 (37.31%)” |
| Dry mouth | “130/328 (39.63%)” | “31/327 (9.48%)” |
| Middle insomnia | “44/328 (13.41%)” | “13/327 (3.98%)” |
| Nausea | “43/328 (13.11%)” | “7/327 (2.14%)” |
| Initial insomnia | “32/328 (9.76%)” | “12/327 (3.67%)” |
| Urinary hesitation | “27/328 (8.23%)” | “2/327 (0.61%)” |
| Somnolence | “24/328 (7.32%)” | “12/327 (3.67%)” |
| Headache | “22/328 (6.71%)” | “23/327 (7.03%)” |
| Dyspepsia | “20/328 (6.10%)” | “7/327 (2.14%)” |
| Urinary tract infection | “20/328 (6.10%)” | “10/327 (3.06%)” |
| Constipation | “19/328 (5.79%)” | “8/327 (2.45%)” |
| Upper respiratory tract infection | “19/328 (5.79%)” | “26/327 (7.95%)” |
| Dizziness | “17/328 (5.18%)” | “6/327 (1.83%)” |
| COVID-19 | “14/328 (4.27%)” | “25/327 (7.65%)” |
Serious adverse events and deaths
| Event | AD109, affected / at risk (%) | Placebo, affected / at risk (%) |
|---|---|---|
| All-cause mortality | “0/328 (0.00%)” | “0/327 (0.00%)” |
| Any serious adverse event | “5/328 (1.52%)” | “10/327 (3.06%)” |
| Acute myocardial infarction | “0/328 (0.00%)” | “1/327 (0.31%)” |
| Aortic dissection | “1/328 (0.30%)” | “0/327 (0.00%)” |
| Intracranial aneurysm | “1/328 (0.30%)” | “0/327 (0.00%)” |
| Ischaemic stroke | “0/328 (0.00%)” | “1/327 (0.31%)” |
| Suicide attempt | “0/328 (0.00%)” | “1/327 (0.31%)” |
Relatedness of serious adverse events as classified in the ClinicalTrials.gov record
Absence of serious adverse events related to AD109
Pooled phase 3 analysis: overall and most common treatment-emergent adverse events
Pooled phase 3 analysis: major adverse cardiovascular events
Pooled phase 3 analysis: heart rate and blood pressure, safety analysis set
| Measure | AD109 (n = 653) | Placebo (n = 646) | p-value |
|---|---|---|---|
| Heart rate, beats/min, mean change (SD) to week 26, evening pre-PSG | “2.0 (11.2)” | “-0.7 (10.0)” | Not reported |
| Heart rate, beats/min, mean change (SD) to week 26, morning post-PSG | “3.4 (9.5)” | “-0.7 (9.4)” | Not reported |
| Heart rate ≥100 beats/min on study, n (%) | “48 (7.4)” | “28 (4.3)” | “0.021” |
| Systolic blood pressure ≥140 mm Hg on study, n (%) | “175 (26.8)” | “168 (26.0)” | “0.760” |
| Diastolic blood pressure ≥90 mm Hg on study, n (%) | “146 (22.4)” | “131 (20.3)” | “0.368” |
Phase 3 program: onset, duration, and severity of insomnia
Study limitations
Summary
- Publication status: results are available from a congress abstract, the registry results (first posted 2026-11-03), company releases, and the prospectus; the 2026 editorial on SynAIRgy described LunAIRo results as forthcoming.
- Design: placebo-controlled for 51 weeks, with the primary endpoint at week 26; week 51 efficacy was analyzed as a tertiary endpoint. No active comparator was used, dose reduction was not permitted, and all 64 sites were in the United States.
- Population: adults intolerant of or refusing PAP with a PROMIS-Fatigue raw score of at least 17, and a BMI cap of 40 (men) or 42 (women) kg/m2. Exclusions included bothersome insomnia, clinically significant cardiac disease, blood pressure above 145/90 mmHg, specified psychiatric disorders, and narrow angle glaucoma.
- Eligibility AHI differs by source: protocol version 4.0 states AHI4 of more than 5 and up to 45, the registry states AHI of more than 5, and the baseline abstract states no upper limit. The design paper states caps could be added during the trial.
- Severity mix: in the pooled phase 3 population, 51% had AHI below 20 events/h and 74% below 30, per the prospectus.
- Endpoint change: the 2025 baseline abstract named the proportion with at least 50% AHI4 reduction at six months as the primary endpoint. Protocol amendment 4.0 (June 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”, after the registry's actual primary completion date (2025-05-07).
- Estimands and missing data: the treatment policy estimand assumed data missing not at random with control-based imputation. The on-treatment estimand excluded data after treatment discontinuation with last observation carried forward and included 240 participants on AD109 and 293 on placebo, against 324 and 326 in the full analysis set. The company states the on-treatment estimand gave the most clinically relevant estimate, and attributes the smaller week 51 response to higher discontinuation with AD109 and control-based imputation. The topline release reported the on-treatment relative reduction (46.8%).
- Analysis-set exclusions: participants at site 1308 were excluded from the full analysis set after the site was terminated.
- Discontinuation: treatment discontinuation due to adverse events was 23.7% with AD109 and 6.6% with placebo by month 6 and 28.6% and 10.0% by month 12; overall treatment discontinuation at month 12 was 46.5% and 25.1% (prospectus, main cohort). In the registry, 250 of 329 participants on AD109 and 274 of 331 on placebo completed the study.
- Patient-reported outcomes: AD109 did not significantly reduce the PROMIS-Fatigue T-score under either estimand, and no treatment effect was observed on PROMIS Sleep Impairment.
- Pooled analyses: Patel et al. (2026a) reports the pooled 39.0% versus 18.8% responder result without an estimand label, while the prospectus labels the pooled 39% as on treatment. The prospectus states the phase 3 trials were not designed or powered to assess cardiovascular outcomes.
- Clinical meaningfulness: at the pre-NDA meeting the FDA gave feedback on the clinical meaningfulness of the primary endpoint results and the limitations of the PROs, and indicated additional analyses and justification may be needed.
- Sponsor: the prospectus describes LunAIRo as a trial the company initiated.
APC-APN-306
Objective
Long-term safety of AD109 in participants completing a parent phase 3 trial
Exploratory objectives: night-to-night variability by ring oximetry and patient-reported outcomes by mobile application
Location and study date
Registry dates and status, last updated May 2025
| Field | Registry entry |
|---|---|
| Study start (actual) | “2024-07-03” |
| Primary completion (estimated) | “2026-06-30” |
| Last update posted | “2025-05-13” |
Completion of the open-label extension in 2026 per the company
Study design
Phase 3, single-group, open-label continuation protocol
Washout before open-label dosing and serial safety assessments
Safety follow-up for up to an additional year after either phase 3 trial
Eligibility criteria
Completion of a parent phase 3 trial without permanent discontinuation of study drug
Treatment
Open-label fixed-dose combination of aroxybutynin and atomoxetine
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Registry primary outcome measures: adverse events, vital sign abnormalities, and concomitant therapy
Safety assessments and exploratory oximetry parameters
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Field | Registry entry |
|---|---|
| Enrollment (estimated) | “1280” |
Description of analysis sets
No evidence found.
Results
Participant disposition
Interim enrollment and uptake of exploratory data collection
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Interim safety conclusion stated without data
Study limitations
Summary
- Design: open-label, single-group continuation study with no comparator; the registered primary outcomes are counts of participants with adverse events, vital sign abnormalities, and concomitant therapy.
- Population: eligibility required completion of a parent phase 3 trial without permanent discontinuation of study drug, so participants who stopped study drug in the parent trials were not eligible.
- Status: the registry record (last updated 2025-05-13) lists an estimated enrollment of 1,280 and an estimated primary completion of 2026-06-30, while the prospectus states the trial was completed in 2026.
- Results: the only results are interim data from a 2025 congress abstract, with 102 participants enrolled (70% of eligible). The abstract states that data collected to date support long-term safety without reporting adverse event data, and no baseline, efficacy, patient-reported outcome, or analysis-set information is available.
- Exploratory ring oximetry and mobile-application PROs were optional; 73 participants (72%) opted in.
- Sponsor: the prospectus states that Syneos provided services to the company in connection with the trial.
MARIPOSA
Objective
Efficacy and safety of AD109 over 4 weeks
“The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic agent aroxybutynin and the norepinephrine reuptake inhibitor atomoxetine, in the treatment of OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The purpose of the present study was to evaluate the efficacy and safety of AD109 over a longer duration (4 wk) in patients with mild to severe OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company-stated objectives, including selection of the aroxybutynin dose for phase 3
Location and study date
Twenty-five U.S. sites, November 2021 to August 2022
“A phase II randomized, double-blind, placebo-controlled, parallel-arms clinical trial was performed at 25 clinical investigative sites in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enrollment began on November 29, 2021 and was completed on August 3, 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry dates
| Field | Registry entry |
|---|---|
| Study start (actual) | “2021-11-29” |
| Primary completion (actual) | “2022-07-20” |
| Study completion (actual) | “2022-08-03” |
Results first posted to the registry in August 2026
Study design
Phase 2, randomized, double-blind, placebo-controlled, parallel-group, 4-week trial
“Phase II randomized, double-blind, placebo-controlled, parallel-group, 4-week trial comparing AD109 2.5/75 mg, AD109 5/75 mg, atomoxetine 75 mg alone, and placebo (www.clinicaltrials.gov identifier NCT 05071612).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who met all enrollment criteria were randomized to one of four treatment arms (AD109 2.5/75 mg, AD109 5/75 mg, Ato75, or placebo) using a randomization ratio of 2:2:3:3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were centrally randomized using an interactive web-based system. Participants, investigators, and study personnel were all blinded to allocation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AD504 arms in the same trial, reported separately
“The study also evaluated another experimental drug (AD504) in early development, and those results will be reported separately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion and exclusion criteria in the publication (AHI4 of 10 to 45 by two polysomnograms)
“Participants were adults with OSA with a mean apnea–hypopnea index using the ⩾4% desaturation criterion for hypopneas (AHI4) of 10–45 based on two screening/baseline polysomnography (PSG) studies, with <25% of events comprising central or mixed apnea.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Age requirement was 18–65 years for men and 18–75 for women. Body mass index was required to be ⩽38 kg/m2 for men and ⩽40 kg/m2 for women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key exclusion criteria were clinically important sleep disorders other than OSA, active cardiac diseases (rhythm disturbance, coronary artery disease, or heart failure), hypertension requiring more than two drugs for control, craniofacial malformation or grade ⩾3 tonsillar hypertrophy, work schedule involving night or shift work, and chronic therapy with monoamine oxidase inhibitors, norepinephrine reuptake inhibitors, α-1 antagonists, tricyclic antidepressants, strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, duloxetine), opioids, muscle relaxants, wake-promoting agents, antipsychotic agents, anticholinergic agents, or warfarin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants treated with CPAP, oral or nasal devices, or positional devices could enroll as long as the devices had not been used for ⩾2 weeks before the first PSG study and were not used during participation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria as stated by the company, including insomnia
Treatment
Nightly dosing with a 1-week lower-dose run-in and no dose reduction
“The study drug was prepared as identical tablets and identical capsules to ensure adequate double-blinding. Participants received a single tablet or a tablet and a capsule.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were instructed to take the study drug nightly immediately before bedtime for 4 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The first week of dosing was with a lower-dose run-in (AD109 2.5/37.5 mg or atomoxetine 37.5 mg), followed by the full dose taken in Weeks 2–4. Dose reduction was not permitted; dosing was discontinued if the study drug was not tolerated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry arm descriptions with the titration dose
Dose notation in the prospectus (aroxybutynin base amounts)
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Primary endpoint in the publication: change in AHI4 for each AD109 dose versus placebo
“The primary endpoint was the change from baseline to weeks 3 and 4 in AHI4 for each AD109 dose versus placebo. The secondary endpoint was the change from baseline to weeks 3 and 4 in AHI4 for Ato75 versus placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although study eligibility was determined by scoring of PSG findings at the individual study sites, endpoint calculation was based on subsequent scoring by a central scoring laboratory (Sleep Strategies).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from the two baseline PSG studies were averaged for analysis, as were data from the two treatment PSG studies (conducted after 3 and 4 weeks of dosing, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endpoints of the trial
Primary endpoint in the registry: combined AD109 arms versus placebo, a difference from the publication
Hypoxic burden as a cardiovascular risk metric
“Hypoxic burden was calculated according to Azarbarzin and colleagues by quantifying the respiratory event–associated area under the desaturation curve for the entire night and dividing by sleep duration to yield a metric expressed in %min per hour of sleep” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the contrary, AD109 has been shown to significantly decrease hypoxic burden, a metric shown to predict adverse cardiovascular outcomes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epworth Sleepiness Scale change compared with the clinically important difference
“Although the change from baseline in Epworth Sleepiness Scale score did not differ versus placebo for any drug regimen, the median change from baseline was similar to the clinically important difference of 2–3 points in CPAP-treated patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AHI as the conventional primary endpoint of OSA trials, per the phase 3 design paper
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power
“Approximately 200 participants were planned for enrollment, with approximately 40 in each AD109 dose group, 60 in the Ato75 group, and 60 in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present study had >90% power to detect a treatment difference on the primary endpoint (AHI4 for AD109 vs. placebo) at a two-sided 0.05 significance level if the true difference between the active arm and placebo arm on AHI4 was 11 units and the within-subject standard deviation was 11.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants randomized and analyzed in the AD109 portion of the trial
Registry enrollment of 294 participants, including the AD504 arms
| Field | Registry entry |
|---|---|
| Enrollment (actual), all arms | “Enrollment (Actual) 294” |
Description of analysis sets
Modified intention-to-treat, intention-to-treat, and safety populations
“According to a predefined statistical analysis plan, there was no prespecified imputation for missing data. Thus, outcomes were analyzed based on the modified intention-to-treat (mITT) population consisting of all participants who were randomized, took at least one dose of any of the study drugs, and had at least one measurement of the primary endpoint.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A post hoc analysis of the primary and secondary outcomes was performed in the ITT population (all individuals who signed the informed consent form and were randomized to any treatment arm) using the baseline observation carried forward to impute missing data. Safety assessments included all participants who received at least one dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analysis methods, sequential testing, and no adjustment for multiplicity
“For the primary efficacy analysis, a repeated-measures model was used to assess the change in AHI4 from baseline for two doses of AD109, Ato75, and placebo. Percent reduction versus placebo was calculated using an analysis of covariance model with log-transformed data to account for the skewed distribution of values and using baseline as a covariate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Primary and secondary hypotheses were tested sequentially. Findings were considered significant if the two-sided P value was less than 0.05. Given the exploratory nature of the trial, no adjustment for multiple comparisons was performed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We present the AD109 doses separately in this article, but we have also included analysis of AHI4 for the combined AD109 doses in Table E2 in the online supplement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry analysis population and the prespecified pooling of AD109 doses
Results
Participant disposition
Screening, randomization, analysis populations, and completion
“Of the 764 subjects screened, 211 were randomized to one of the four treatment arms (Figure 1). Of the 209 individuals who were randomized and received at least one dose of treatment (i.e., safety population), 181 had at least one measurement on the primary endpoint (i.e., mITT population) and 176 completed the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In summary, treatment side effects resulted in one dropout in the placebo arm, 12 in the Ato75 arm, and 5 each in the AD109 2.5/75 mg and AD109 5/75 mg arms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographic and clinical characteristics of the safety population
Baseline AHI4 (4% desaturation hypopnea criterion) by arm
| Arm | Baseline AHI4, events/h, median (IQR) |
|---|---|
| Placebo | “20.1 (11.9–25.9)”View highlighted excerpt for this quote |
| Atomoxetine 75 mg | “19.0 (11.8–28.8)”View highlighted excerpt for this quote |
| AD109 2.5/75 mg | “20.5 (12.3–27.2)”View highlighted excerpt for this quote |
| AD109 5/75 mg | “19.4 (13.7–26.4)”View highlighted excerpt for this quote |
Inclusion of participants with AHI4 below 10 after central scoring
Registry baseline age and body mass index, safety set of all arms
| Characteristic | AD109 75/5mg | AD109 75/2.5mg | Atomoxetine 75mg | Placebo | Total (all six arms) |
|---|---|---|---|---|---|
| Participants | “41” | “42” | “63” | “63” | “292” |
| Age, years, mean (SD) | “54.2(9.24)” | “51.5(9.22)” | “52.8(10.95)” | “54.9(9.03)” | “54.2(9.49)” |
| BMI, kg/m2, mean (SD) | “31.12(4.085)” | “33.43(4.352)” | “31.16(4.716)” | “31.17(4.719)” | “31.65(4.389)” |
Efficacy results
Primary endpoint: AHI4 (4% desaturation hypopnea criterion), mITT
“Apnea–hypopnea index with a 4% desaturation criterion (primary outcome) was reduced from a median (IQR) of 20.5 (12.3–27.2) to 10.8 (5.6–18.5) in the AD109 2.5/75 mg arm (−47.1%), from 19.4 (13.7–26.4) to 9.5 (6.1–19.3) in the AD109 5/75 mg arm (−42.9%; both P < 0.0001 vs. placebo), and from 19.0 (11.8–28.8) to 11.8 (5.5–21.5) with atomoxetine alone (−38.8%; P < 0.01 vs. placebo). Apnea–hypopnea index with a 4% desaturation criterion decreased from 20.1 (11.9–25.9) to 16.3 (11.1–28.9) in the placebo arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both doses of AD109 significantly decreased AHI4 compared with placebo, with mean (95% confidence interval) decreases of −7.16 (−11 to −3.3) events/h for the 2.5/75 mg dose and −7.2 (−10.97 to −3.4) for the 5/75 mg dose (P < 0.001 for both). These decreases represent a placebo-adjusted reduction in AHI4 of 47.1% (27.9–61.2) and 42.9% (22.2–58) for the two doses, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Respiratory parameters from polysomnography: AHI4 (4% desaturation hypopnea criterion)
Respiratory parameters: AHI3a (3% desaturation or arousal hypopnea criterion)
Respiratory parameters: AHI4 (4% criterion) in NREM and REM sleep
REM sleep, sleep position, and the 3% or arousal hypopnea definition in the text
“The effects of AD109 on AHI4 were statistically significant in non-REM (NREM) sleep and in the supine and lateral positions. AD109 also decreased the AHI when hypopneas were scored using ⩾3% desaturation or arousal criteria (P < 0.01 for both doses).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although AD109 2.5/75 mg significantly reduced AHI4 during REM sleep versus baseline (P = 0.044), the reduction was not significant when adjusted for placebo (P = 0.116), possibly because limited data were available during REM sleep during treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hypoxic burden
“Compared with placebo, hypoxic burden was reduced by −12.7 (−24.3 to −1.14) %min/h (P = 0.03) with AD109 2.5/75 mg and by −16.6 (−28 to −5.2, P = 0.005) with AD109 5/75 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Arm | Hypoxic burden at baseline, geometric mean (95% CI), %min/h | Hypoxic burden on treatment, geometric mean (95% CI), %min/h |
|---|---|---|
| Placebo | “31.1 (25.8–38.2)”View highlighted excerpt for this quote | “30.1 (25.0–38.3)”View highlighted excerpt for this quote |
| Atomoxetine 75 mg | “31.9 (27.2–40.5)”View highlighted excerpt for this quote | “18.0 (12.4–26.0)”View highlighted excerpt for this quote |
| AD109 2.5/75 mg | “31.0 (25.1–41.2)”View highlighted excerpt for this quote | “19.1 (11.3–28.2)”View highlighted excerpt for this quote |
| AD109 5/75 mg | “32.4 (25.6–41.5)”View highlighted excerpt for this quote | “18.0 (12.0–26.1)”View highlighted excerpt for this quote |
Oxygen desaturation index (4% criterion) and time below 90% saturation, placebo-adjusted
| Arm | ODI4, placebo-adjusted change, LS mean (95% CI) | T90, placebo-adjusted change, LS mean (95% CI) |
|---|---|---|
| Atomoxetine 75 mg | “−4.82 (−8.16 to −1.49)”View highlighted excerpt for this quote | “−5.56 (−12.67 to 1.56)”View highlighted excerpt for this quote |
| AD109 2.5/75 mg | “−5.63 (−9.38 to −1.89)”View highlighted excerpt for this quote | “−3.20 (−11.12 to 4.72)”View highlighted excerpt for this quote |
| AD109 5/75 mg | “−6.01 (−9.71 to −2.30)”View highlighted excerpt for this quote | “−3.68 (−11.50 to 4.15)”View highlighted excerpt for this quote |
Responders: more than 50% reduction in AHI4 (4% criterion)
| Arm | Proportion (95% CI) with more than 50% reduction in AHI4 | Odds ratio versus placebo |
|---|---|---|
| Placebo | “16.6 (8.4–28.3)”View highlighted excerpt for this quote | Not applicable |
| Atomoxetine 75 mg | “39.4 (25.8–54.3)”View highlighted excerpt for this quote | “3.47 (1.57–7.71)”View highlighted excerpt for this quote |
| AD109 2.5/75 mg | “43.2 (26.3–61.4)”View highlighted excerpt for this quote | “4.00 (1.68–9.51)”View highlighted excerpt for this quote |
| AD109 5/75 mg | “44.3 (27.6–62.0)”View highlighted excerpt for this quote | “4.23 (1.80–9.97)”View highlighted excerpt for this quote |
Resolution to AHI4 below 10 events per hour by baseline severity (4% criterion)
“However, a higher proportion of participants with a baseline AHI4 in the mild to moderate range (AHI4 10–30 events/h) experienced a resolution of OSA (defined as AHI4 <10 events/h) compared with those with a baseline AHI4 in the severe range (AHI4 ⩾30; 52.2% vs. 7%; P = 0.004; Figure E2 in the online supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the mITT population, a significant reduction in AHI4 occurred in patients with a baseline AHI4 as high as 45 events per hour, although fewer patients with severe OSA at baseline (AHI4 ⩾30) had an AHI4 <10 during treatment (7%) compared with those with mild (AHI4 10–15, 77%) or moderate (AHI4 15–30, 42%) OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post hoc analyses showed no statistically significant differences in AHI4 reduction between subgroups based on age, sex, obesity, or baseline OSA severity (Tables E4–E7 in the online supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Post hoc intention-to-treat analysis of AHI4 (4% criterion)
“Post hoc analysis of the primary and secondary outcomes using the ITT population and considering zero change from baseline for missing data showed results similar to those in the mITT population. Compared with placebo, AHI4 decreased by −5.9 (−9.4 to −2.4) events/h (P = 0.001) with AD109 2.5/75 mg, by −6.3 (−9.8 to –2.8, P < 0.001) with AD109 5/75 mg, and by −4.3 (−7.5 to −1.2, P = 0.007) with Ato75.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry primary outcome: change in AHI4 (4% criterion), combined AD109 arms, mITT
| Group | Participants analyzed | LS mean change from baseline (95% CI), events/hr |
|---|---|---|
| AD109 combined dose arms | “69” | “-7.38 (-9.53 to -5.23)” |
| AD109 75/5mg | “35” | “-7.40 (-10.41 to -4.38)” |
| AD109 75/2.5mg | “34” | “-7.37 (-10.44 to -4.30)” |
| Placebo | “62” | “-0.21 (-2.49 to 2.07)” |
Atomoxetine alone versus AD109: respiratory effect and sleep disruption
“Ato75 alone reduced AHI4 by −5.19 (−8.6 to −1.8) events/h, or by 38.8% (19.5–53.6) compared with placebo (P = 0.003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ato75 did not differ from either dose of AD109 in any respiratory parameter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AD109 did not differ significantly from atomoxetine alone (Ato75) for most respiratory parameters, suggesting that the noradrenergic activity of atomoxetine is primarily responsible for the effect of AD109 on upper airway obstruction. However, Ato75 was more likely to disturb sleep than AD109 based on objective and subjective measurements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, Ato75 alone, despite improvements in sleep-disordered breathing, was not sufficiently well tolerated to be a standalone treatment for OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sleep architecture: total sleep time, REM sleep, and wake after sleep onset
“Total sleep time (TST) did not change with AD109 compared with placebo. However, Ato75 reduced TST by 21.5 (8.6–34.3) minutes compared with placebo (P = 0.001) and by 23.93 (8.89–38.98) and 16.09 (1.24–30.94) minutes compared with AD109 2.5/75 mg and 5/75 mg, respectively (P = 0.002 and P = 0.03). AD109 and Ato75 increased NREM stages 1 and 2 and reduced REM sleep compared with placebo (P < 0.001 for all).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose selection for phase 3
“The present study and the study of Rosenberg and colleagues suggest that the optimal dosage for AD109 may be 2.5/75 mg (21). A lower dose of atomoxetine appears to be less effective in decreasing OSA severity, and a higher dose of aroxybutynin increases antimuscarinic side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
PROMIS-Fatigue improvement with AD109 2.5/75 mg only
“There was a significant improvement of Patient-Reported Outcome Measurement Information System (PROMIS) fatigue scores with AD109 2.5/75 mg compared with placebo (−3.56 [−6.77 to −0.35]; P < 0.05) and Ato75 (−3.49 [−6.84 to −0.13]; P < 0.05; Figure 4 and Table 5). There was no significant improvement in subjective outcomes with Ato75 versus placebo. However, the PROMIS sleep disturbance scale showed a trend toward increasing (i.e., worsening) with Ato75 compared with placebo (P = 0.056).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is unclear why we did not see improvement with the higher dose of AD109, although higher rates of daytime symptoms such as dry mouth, urinary hesitation, constipation, and somnolence were reported with the higher dose of aroxybutynin, suggesting more tolerability issues with the AD109 5/75 mg dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes, placebo-adjusted change from baseline
Subset with patient-reported outcome assessments
“Medians (IQR) were calculated from mITT set for the subset of patients with an assessment of patient-reported outcomes at baseline and on treatment (placebo, n = 57/62; ato75, n = 48/50; AD109 2.5/75, n = 32/34; AD109, 5/75 n = 35/35).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Placebo response and mild baseline symptoms as explanations offered by the authors
“The lack of significant improvement compared with placebo on most of the patient-reported outcomes is likely related to the strong placebo effect that is common in such subjective measures (33). Indeed, most measures showed significant change from baseline in all treatment groups, including placebo. The results may also have been affected by the generally mild symptoms reported by our patient population at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Overall adverse events, discontinuations due to adverse events, and no serious adverse events
“No serious adverse events were reported. A total of 373 adverse events were reported in 104 (49.8%) participants in the safety population: 26 (61.9%) individuals treated with AD109 2.5/75 mg, 32 (78.0%) treated with AD109 5/75 mg, 51 (81.0%) treated with Ato75, and 25 (39.7%) treated with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-three (11%) individuals discontinued study participation because of adverse events: 5 (12%) in each of the AD109 groups, 12 (19%) in the atomoxetine group, and 1 (2%) in the placebo group. Events leading to study discontinuation in at least three participants were insomnia, nausea, and dry mouth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most events were rated as mild. Two events classified as serious (nausea and migraine) led to study discontinuation in two participants in the Ato75 group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Most common adverse events (at least three participants in any group)
Dose-dependent dry mouth and insomnia with atomoxetine alone
“Dry mouth was a common side effect with all three drug regimens, but was much more common with AD109 5/75 mg, suggesting a dose-dependent increase with aroxybutynin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Insomnia was also the most frequently reported adverse event with Ato75 and led to study discontinuation in six individuals (6.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heart rate and blood pressure versus placebo
“Placebo-adjusted mean (95% confidence interval) change from baseline in overnight heart rate was slightly higher in all treatment groups: 7.7 (5.7–9.6), 5.1 (2.9–7.4), and 5.5 (3.3–7.1) beats/min for Ato75, Ad109 2.5/75 mg, and AD109 5/75 mg, respectively (Table 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diastolic blood pressure was slightly higher for the AD109 2.5/75 mg group in the evening and in the morning, at 4.7 (1.1–8.3) and 4.2 (0.5–7.9) mm Hg, respectively (Table 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, because there is an increased risk for cardiovascular disease in the OSA population, small increases in heart rate may potentially be more clinically important.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present trial data do not provide a definitive conclusion or understanding of the AD109 pressor effect in OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weight and psychometric tests
“There was no reduction in weight across all treatment arms. Results of the psychometric tests are reported in the online supplement (see Figure E1 and Table E3) and were not different compared with placebo across all treatment arms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry adverse event table, other (not serious) events at a 5% threshold
| Adverse event | AD109 75/5mg | AD109 75/2.5mg | Atomoxetine 75mg | Placebo |
|---|---|---|---|---|
| Total, other adverse events | “32/41 (78.05%)” | “26/42 (61.90%)” | “51/63 (80.95%)” | “25/63 (39.68%)” |
| Dry mouth | “24/41 (58.54%)” | “10/42 (23.81%)” | “20/63 (31.75%)” | “10/63 (15.87%)” |
| Middle insomnia | “4/41 (9.76%)” | “8/42 (19.05%)” | “13/63 (20.63%)” | “1/63 (1.59%)” |
| Initial insomnia | “2/41 (4.88%)” | “3/42 (7.14%)” | “7/63 (11.11%)” | “1/63 (1.59%)” |
| Urinary hesitation | “4/41 (9.76%)” | “0/42 (0.00%)” | “5/63 (7.94%)” | “0/63 (0.00%)” |
| Nausea | “4/41 (9.76%)” | “5/42 (11.90%)” | “4/63 (6.35%)” | “2/63 (3.17%)” |
| Constipation | “5/41 (12.20%)” | “0/42 (0.00%)” | “2/63 (3.17%)” | “2/63 (3.17%)” |
Registry serious adverse events
| Measure | AD109 75/5mg | AD109 75/2.5mg | Atomoxetine 75mg | Placebo |
|---|---|---|---|---|
| Serious adverse events | “0/41 (0.00%)” | “0/42 (0.00%)” | “0/63 (0.00%)” | “0/63 (0.00%)” |
Study limitations
Summary
- Design: phase 2 dose-finding trial with 4 weeks of dosing; the authors describe its exploratory nature, and no adjustment for multiple comparisons was made.
- Population: AHI4 of 10 to 45 on two baseline polysomnograms, ages 18 to 65 (men) or 18 to 75 (women), and BMI up to 38 (men) or 40 (women) kg/m2. Exclusions included other clinically important sleep disorders (the prospectus names a history of insomnia), active cardiac disease, and hypertension requiring more than two drugs. PAP intolerance was not required; prior device users enrolled after 2 weeks without use, and 42.9% to 50.2% of each arm reported CPAP use.
- Eligibility scoring: eligibility used site scoring, and endpoints used central scoring, which led to inclusion of 29 participants with baseline AHI4 below 10 after central scoring.
- Primary endpoint differs by source: the publication tests each AD109 dose against placebo, and the registry names the combined AD109 arms against placebo. The registry states the trial was not powered to compare individual doses and that individual dose results should be interpreted descriptively.
- Missing data: the statistical analysis plan had no prespecified imputation, so efficacy used the modified intention-to-treat population (181 of 211 randomized); the intention-to-treat analysis was post hoc.
- Discontinuation: study discontinuation due to adverse events was 5 (12%) in each AD109 group, 12 (19%) with atomoxetine alone, and 1 (2%) with placebo.
- Outcomes: the authors attribute the lack of PRO differences to a placebo effect and mild baseline symptoms, PROs were analyzed in the subset with assessments, and the authors suggest limited REM data during treatment as a possible reason the REM reduction was not significant versus placebo.
- Reporting: registry enrollment of 294 includes two AD504 arms reported separately, and registry results were first posted on 2026-08-12, after study completion on 2022-08-03.
- Source discrepancies: the publication states no serious adverse events were reported and also that two events classified as serious led to discontinuation with atomoxetine alone, while the registry lists 0 serious adverse events in every arm. Dry mouth with placebo is 3 (5%) in the publication and 10/63 (15.87%) in the registry. The prospectus gives a start in December 2021, and the registry and publication give November 29, 2021.
- Sponsor: the prospectus describes MARIPOSA as a trial the company initiated.
APC-APN-201
Objective
Pharmacokinetics, efficacy, tolerability, and safety with concomitant GLP-1 receptor agonists
Location and study date
Registered study dates and sites
| Field | Quoted record |
|---|---|
| Study start (actual) | “2024-05-20” |
| Primary completion (actual) | “2024-12-26” |
| Number of locations | “This study has 4 locations” |
| Alabama site | “Anniston, Alabama, United States, 36207 Pinnacle Research Group, LLC” |
| Florida site | “Jacksonville, Florida, United States, 32256 Clinical Neuroscience Solutions, Inc” |
| North Carolina site | “Monroe, North Carolina, United States, 28112 Monroe Biomedical Research” |
| Tennessee site | “Memphis, Tennessee, United States, 38119 Clinical Neuroscience Solutions, Inc” |
Study design
Open-label, parallel-arm, 6-week phase 2 design
Arms defined by concomitant GLP-1 receptor agonist use
Registered design details
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Inclusion: age, body mass index, and REI4 range on home sleep apnea testing
Inclusion: stable GLP-1 receptor agonist dose or eligibility for one
Exclusion: insomnia, urinary, glaucoma, psychiatric, and bariatric surgery criteria
Treatment
Registered arms and administration
Permitted GLP-1 receptor agonists
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Primary outcome: spontaneously reported adverse events at 6 weeks
Efficacy outcome: REI4 responder at week 5 by home sleep apnea test
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “Enrollment (Actual) 40” |
Description of analysis sets
Pharmacokinetic analysis: noncompartmental analysis and mixed-effects model
Results
Participant disposition
Participants enrolled and treated by arm
Baseline characteristics
No evidence found.
Efficacy results
REI4 responder rate at week 5 with and without a GLP-1 receptor agonist
Pharmacokinetics: geometric mean ratios with versus without a GLP-1 receptor agonist
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events, serious events, and deaths
Study limitations
Summary
- Design: open-label, 6-week phase 2 study with no placebo arm; the arms differ only in concomitant GLP-1 receptor agonist use, while the registry lists the allocation as randomized.
- Size: 40 participants at 4 U.S. sites, with 22 receiving AD109 alone and 18 receiving AD109 with a GLP-1 receptor agonist, against about 20 planned per arm.
- Population: ages 18 to 75, BMI 27 to 43 (men) or 45 (women) kg/m2, and REI4 above 5 and below 45 on home sleep apnea testing. Exclusions included bothersome insomnia or bladder outlet obstruction, narrow angle glaucoma, and prior gastric weight loss surgery. Prior device users enrolled after 2 weeks without use.
- Endpoints: the primary outcome was spontaneously reported adverse events. Efficacy was the proportion with at least 50% REI4 reduction on home sleep apnea testing at week 5, reported as 33.3% and 29.4%.
- Reporting: results are available only from a congress abstract, without baseline characteristics or PROs.
- Sponsor: the abstract states the study was supported by Apnimed.
APC-004
Objective
Effect of two AD109 doses on hypoxic burden and AHI over a single night
Rationale for testing a lower atomoxetine dose in mild to low-moderate OSA
“In this trial, we studied patients with mild or low-moderate OSA (AHI between 5 and 20 events/h), as we hypothesized that this group of patients could be treated with a lower dose of the combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, a lower dose of atomoxetine could help to reduce side effects and improve long-term tolerance in this population if the efficacy was comparable to the higher dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose finding as described by the company
Location and study date
Registered study dates and sites
| Field | Quoted record |
|---|---|
| Study start (actual) | “2020-12-22” |
| Primary completion (actual) | “2021-05-31” |
| Number of locations | “This study has 3 locations” |
| California site | “San Diego, California, United States, 92103 Pacific Research Network” |
| Georgia site | “Atlanta, Georgia, United States, 30328 NeuroTrial Research” |
| Pennsylvania site | “Philadelphia, Pennsylvania, United States, 19063 Brian Abaluck, LLC” |
Study design
Randomized, double-blind, placebo-controlled, 3-period single-dose crossover
“This study was a randomized, double-blind, placebo-controlled, 3-period, single-dose crossover study that evaluated the safety and efficacy of 2 different dose combinations of AD109 (atomoxetine plus R-oxybutynin) in participants with mild to moderate OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who met all enrollment criteria were centrally randomized to receive the following oral treatments prior to a single night PSG, separated by at least a 1-week washout period:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Six registered treatment sequences
Standard and lower dose comparison as described by the company
Eligibility criteria
Inclusion: age, body mass index, AHI4 of 5 to 20 events/h, and symptoms
“Participants had to be between 25 and 65 years of age (inclusive) at the screening visit and have a body mass index between 18.5 and 40.0 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The screening PSG had to demonstrate an AHI (hypopneas scoring required a 4% drop in peripheral capillary oxygen saturation [SpO2]) of 5–20 events/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had to also report minimal self-reported symptomatology, such as a score ≥ 1 on the Patient Global Impression of severity (PGI-S) or history of 1 or more of the following OSA symptoms: snoring or nighttime gasping/choking, daytime sleepiness, fatigue, or decreased concentration, nonrefreshing sleep, sleep fragmentation (including from nocturia), or morning headache, irritability, decreased mood or libido.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion: other sleep disorders, interacting medications, and unstable disease
“Patients could not have another active sleep disorder or be on any medication that could affect respiratory, muscle, or neurologic function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants could also not have any other major organ system disease or unstable medical disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion: registered cardiac and CPAP criteria
Exclusion: insomnia, psychiatric, neurologic, constipation, and urinary retention criteria as described by the company
Treatment
High-dose and low-dose AD109 and placebo at bedtime
“Each received low-dose AD109 (37.5/2.5 mg), high-dose AD109 (75/2.5 mg), and placebo at bedtime across 3 overnight periods in a randomized order.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dosing of the study treatment occurred immediately prior to lights out.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aroxybutynin 2.5 mg with two atomoxetine doses
“in this trial we tested the effect of aroxybutynin, a purified version of the R-enantiomer not yet commercially available, at the dose of 2.5 mg, combined with 2 doses of atomoxetine (37.5 and 75 mg) on OSA severity in a randomized, placebo-controlled, crossover trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using hypoxic burden as the primary endpoint
Authors' rationale: hypoxic burden as a predictor of cardiovascular morbidity and mortality
“In this trial, we chose the sleep apnea-specific HB instead of the more traditional AHI as our primary outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HB has been recently introduced as a new metric to stratify OSA severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of such studies showed that the HB is a better predictor of the cardiovascular morbidity and mortality linked to OSA compared to AHI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hypoxic burden definition in the publication: all apneas and hypopneas regardless of desaturation
“The primary objective outcome was the HB of sleep apnea, which is calculated as the area under the curve of the baseline oxygen saturation and represents the real ventilatory deficit of the disorder as it considers the frequency, length, and the depth of the obstructive events, whereas AHI simply represents the frequency of the same events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For each apnea or hypopnea (regardless of associated desaturation), the pre-event baseline saturation was defined as the maximum SpO2 during the 100 seconds prior to the end of the event and the area under this baseline value is calculated over a subject-specific search window, which was defined individually for each study, by averaging the SpO2 curve with respect to the end of all events occurring in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The hypoxic burden was then obtained by adding these individual desaturation areas and dividing the total area by the sleep duration, with the units of hypoxic burden being (%min)/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hypoxic burden definition in the registry: events with 4% or greater desaturation
Primary and key secondary endpoints as described by the company
Editorial comment on hypoxic burden as the primary endpoint
“The primary endpoint of hypoxic burden is a laudable choice that highlights the movement away from solely relying on AHI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further validation of this parameter is needed, but inclusion of hypoxic burden in the efficacy of new therapies is warranted and adds to the strength of the findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other outcomes: polysomnography scoring, sleepiness, and vital signs
“Standard overnight PSGs were recorded and scored in accordance with the American Academy of Sleep Medicine scoring manual.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Effects on situational, self-reported sleepiness were assessed by the Karolinska Sleepiness Scale, administered on the morning following each PSG test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the following morning, blood pressure and heart rate were measured in the seated posture.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power
“A total of 30 participants was planned to enter the 3-treatment crossover study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was planned to have 80% power to detect a treatment difference on the primary endpoint at a 2-sided 0.05 significance level, if the true difference of hypoxic burden between treatments was at least -3.7 (%min)/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This assumed that the within-participant standard deviation was 9 and a discontinuation rate of less than 20%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants analyzed for the primary outcome in the registry
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “Enrollment (Actual) 32” |
| Participants analyzed for the primary outcome, each comparison | “Overall Number of Participants Analyzed 27 27 27” |
Description of analysis sets
Statistical methods: repeated-measures model, log transformation, and three comparisons per endpoint
“In general, continuous variables were summarized by presenting medians and interquartile ranges due to the skewed distribution of most variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the known logarithmic distribution of HB, the primary analysis of HB was performed also after log10 (HB + 1) transformation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each endpoint for this study implicitly contained 3 hypothesis tests based on comparisons between study treatments: (1) 75/2.5 dose vs placebo, (2) 37.5/2.5 dose vs placebo, (3) 37.5/2.5 dose vs 75/2.5 dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A repeated-measures model was used to compare log10(HB+ 1), HB (without log-transformation), AHI, and other PSG variables between treatment arms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety analysis methods
“The analyses were descriptive and were based on the safety set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety assessments were summarized by the study treatment the participant received within each period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Screening, randomization, completion, and withdrawals
“A total of 65 participants signed the informed consent form and were enrolled in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-three participants failed screening and 32 participants were randomized (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One ineligible participant was inadvertently randomized but not treated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four participants were treated but terminated before completing the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three patients withdrew for personal reasons and one for an adverse event (severe oxygen desaturation during sleep), which raised the safety risk according to one of the study investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry participant flow
Completion as reported by the company
Baseline characteristics
Demographics of the safety population
“Patient median (interquartile range) age was 53 years (47 to 62) and body mass index was 30.4 kg/m2 (27.0 to 33.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 11 female patients (35.5% of the total) and participants were mostly white (71%) and African American (23%), with the remaining patients (n = 2) having multiple ethnicities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-five (80.6%) participants were not Hispanic or Latino.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline polysomnography, median (interquartile range), AHI and ODI with 4% desaturation criterion
| Parameter | Baseline (n = 31) |
|---|---|
| Log10 (HB + 1) | “1.11 (0.76–1.32)”View highlighted excerpt for this quote |
| HB, (%min)/h | “11.8 (4.8 to 20.0)”View highlighted excerpt for this quote |
| AHI, events/h | “13.5 (8.1 to 17.0)”View highlighted excerpt for this quote |
| AHI supine, events/h | “18.6 (11.3 to 29.1)”View highlighted excerpt for this quote |
| ODI 4%, events/h | “10.0 (6.0 to 15.4)”View highlighted excerpt for this quote |
Registry baseline hypoxic burden, median (full range)
| Field | Quoted record |
|---|---|
| Hypoxic burden, (%*min)/hour | “11.8 (2.08 to 87.78)” |
| Measure description | “Hypoxic burden is a measure of the overall burden of de-oxygenation (hypoxia) due to upper airway obstructive events for every hour of sleep, measured from the SaO2 signal on the polysomnography done overnight.” |
Efficacy results
Hypoxic burden and AHI4 on a single night: high and low dose versus placebo
“Median [interquartile range] hypoxic burden for participants on placebo was 13.9[4.5–21.9] (%min)/h vs 2.3[0.1–10.5] (%min)/h for patients on the high dose (P < .001) and to 7.3[2–12.5] (%min)/h on the low dose (P < .01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Apnea-hypopnea index went from a median of 13.2[8.0–19.1] events/h on placebo reduced to 5.5[2.2 to 9.6] events/h on the high dose (P < .001) and to 7.8[4–13.7] events/h on the low dose (P < .05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Respiratory polysomnography parameters by treatment, median (interquartile range), AHI and ODI with 4% desaturation criterion
Dose response and hypoxic burden responders
“AHI and Log10(HB + 1) were also significantly improved on AD109 high dose compared to low dose, suggesting a dose-related effect size.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Note that > 70% of patients had a reduction of at least 30% in HB and > 40% of participants had a reduction in HB > 90% on high-dose AD109.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AHI4 by body position and sleep stage
“The effect on the AHI was maintained when analysis was limited to the supine position and was present in both non-rapid eye movement and rapid eye movement (REM) sleep, although the reduction in AHI did not reach statistical significance in REM (P = .12 on high dose vs placebo) probably because only 13 participants had REM on both placebo and high dose AD109, and thus the analysis lacked of statistical power.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no relationship between the reduction in REM sleep and the reduction in overall AHI for both the low dose (P = .12, r2 = 0.11) or the high dose of AD109 (P = .56, r2 = 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry primary outcome: mean difference in hypoxic burden (95% confidence interval), events with 4% or greater desaturation
| Comparison | Log10 HB, difference in log10HB[(%*min)/h] | Raw HB, (%*min)/h |
|---|---|---|
| AD109 dose 1 (atomoxetine 75 mg) vs placebo | “-0.40 (-0.54 to -0.25)” | “-6.90 (-10.20 to -3.60)” |
| AD109 dose 2 (atomoxetine 37.5 mg) vs placebo | “-0.21 (-0.36 to -0.07)” | “-4.70 (-8.01 to -1.38)” |
| Dose 2 vs dose 1 | “0.18 (0.04 to 0.33)” | “2.20 (-1.23 to 5.36)” |
Percentage reductions in hypoxic burden and AHI4 versus placebo, as reported in the company prospectus
Health-related quality of life and patient-reported outcomes
Karolinska Sleepiness Scale the morning after dosing
“Subjectively, the proportion of nonsleepy patients, defined by a Karolinska Sleepiness Scale < 5, was 0.83 (95% confidence interval 0.69 to 0.97) on placebo, 0.93 (0.83 to 1.00) on low-dose AD109, and 0.86 (0.74 to 0.99) on high-dose AD109.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These different outcomes between treatments were not statistically significant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Treatment-emergent adverse events in at least 2 participants, safety population
Most frequent adverse events and authors' safety assessment
“The most frequently reported treatment emergent adverse effects occurring in at least 2 study participants were dry mouth (3 [9.7%] participants), decreased appetite (2 [6.5%] participants), and thirst (2 [6.5%] participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both high-dose AD109 and low-dose AD109 were safe and well-tolerated, without clear difference between the high and low doses or between the active doses and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry adverse events: deaths, serious adverse events, and other adverse events at a 5% threshold
| Event | AD109 dose 1 (75 mg) | AD109 dose 2 (37.5 mg) | Placebo |
|---|---|---|---|
| All-cause mortality | “0/30 (0.00%)” | “0/28 (0.00%)” | “0/29 (0.00%)” |
| Other adverse events, total | “4/30 (13.33%)” | “2/28 (7.14%)” | “2/29 (6.90%)” |
| Dry mouth | “2/30 (6.67%)” | “1/28 (3.57%)” | “0/29 (0.00%)” |
| Decreased appetite | “2/30 (6.67%)” | “0/28 (0.00%)” | “0/29 (0.00%)” |
Sleep architecture and arousals
“As shown in Table 2, a high dose of AD109 reduced total sleep time and sleep efficiency and increased wake after sleep onset compared to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, both doses reduced REM sleep and increased N1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The high dose of AD109 reduced the respiratory arousals, but both doses increased the number of spontaneous arousals (ie, not associated with respiratory events or leg movements), so that the total number of arousals was increased on AD109 (P < .05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sleep and morning vital signs by treatment, median (interquartile range)
Study limitations
Summary
- Design: single-dose crossover with one night of polysomnography per treatment, separated by washouts of at least 1 week.
- Population: AHI4 of 5 to 20 events/h, ages 25 to 65, and BMI 18.5 to 40.0 kg/m2, with exclusion of other active sleep disorders, medications affecting respiratory, muscle, or neurologic function, and unstable medical disorders (the prospectus names a history of insomnia). The registry describes the population as mild obstructive sleep apnea, and the publication as mild or low-moderate OSA.
- Size: 32 participants were randomized, 31 were treated, and 27 were analyzed for each primary comparison in the registry.
- Hypoxic burden definition differs by source: the publication includes each apnea or hypopnea regardless of associated desaturation, and the registry includes events with 4% or greater desaturation. An accompanying editorial states that further validation of the measure is needed.
- REM analysis: only 13 participants had REM sleep on both placebo and high-dose AD109, which the authors state left the REM analysis without statistical power.
- Funding: the publication states the study was funded by Apnimed.
APC-003
Objective
Contribution of each component to the efficacy of AD109
Location and study date
Registered study dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2020-10-27” |
| Primary completion (actual) | “2021-05-28” |
Study design
Four-period single-dose randomized crossover
Double-blind crossover with one-week washouts and no replacement of withdrawals
Four-week open-label extension
Eligibility criteria
Registered exclusion: cardiac disease, hypertension, and CPAP use
Inclusion and exclusion as described by the company: AHI 10 to 45 events/h and low upper airway collapsibility
Treatment
Four single-dose treatments in oral capsules
Doses as described by the company, crossover and open-label extension
Study outcomes
Rationale for using hypoxic burden as the primary endpoint
Registered primary outcome: change in log10 hypoxic burden, events with 4% or greater desaturation
Primary and key secondary endpoints as described by the company
Company rationale for oxygenation measures alongside AHI
Other registered assessment: Digit Symbol Substitution Test
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled and analyzed participants in the registry
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “Enrollment (Actual) 60” |
| Participants analyzed for the primary outcome | “Fifty-nine (98.3%) participants were included in the mITT Population” |
Description of analysis sets
Modified intention-to-treat set for efficacy and safety reporting by treatment
Results
Participant disposition
Screening, randomization, and participant flow by period
Participants starting and completing each period, with reasons for not completing
| Period | Started | Completed | Reasons not completed |
|---|---|---|---|
| First intervention | “Started 60” | “Completed 57” | “Incorrectly Randomized 1 Lost to Follow-up 1 Physician Decision 1” |
| Second intervention | “Started 56” | “Completed 56” | “Not Completed 0” |
| Fourth intervention | “Started 49” | “Completed 49” | “Not Completed 0” |
Open-label extension participation
Baseline characteristics
Registry baseline characteristics
| Characteristic | All study participants (n = 60) |
|---|---|
| Sex | “Female 25 Male 35” |
| Ethnicity | “Hispanic or Latino 16 Not Hispanic or Latino 44” |
| Race | “Asian 1 Native Hawaiian or Other Pacific Islander 0 Black or African American 11 White 47 More than one race 1” |
| Body mass index, median (full range), kg/m^2 | “33 (22 to 39)” |
Baseline AHI with 4% desaturation criterion as reported by the company
Efficacy results
Registry primary outcome: least squares mean change in log10 hypoxic burden (95% confidence interval), events with 4% or greater desaturation, mITT
| Treatment | Log10HB4%[%min/hour] |
|---|---|
| AD109 (n = 59) | “-0.41 (-0.54 to -0.28)” |
| Atomoxetine (n = 59) | “-0.36 (-0.49 to -0.23)” |
| R-oxybutynin (n = 59) | “-0.04 (-0.17 to 0.09)” |
| Placebo (n = 59) | “-0.06 (-0.18 to 0.07)” |
Hypoxic burden and AHI4 on the first night and at week 4 of the open-label extension, as reported in the company prospectus
Health-related quality of life and patient-reported outcomes
Simplified Sleep Apnea Quality of Life Index versus baseline, as reported in the company prospectus
Safety results
Registry adverse events: deaths, serious adverse events, and other adverse events at a 3% threshold
| Event | A: AD109 | B: Atomoxetine 75 mg + placebo | C: R-oxybutynin 2.5 mg + placebo | D: Placebo + placebo |
|---|---|---|---|---|
| All-cause mortality | “0/56 (0.00%)” | “0/54 (0.00%)” | “0/54 (0.00%)” | “0/57 (0.00%)” |
| Serious adverse events, total | “1/56 (1.79%)” | “0/54 (0.00%)” | “0/54 (0.00%)” | “0/57 (0.00%)” |
| Atrial fibrillation (serious) | “1/56 (1.79%)” | “0/54 (0.00%)” | “0/54 (0.00%)” | “0/57 (0.00%)” |
| Seizure (serious) | “1/56 (1.79%)” | “0/54 (0.00%)” | “0/54 (0.00%)” | “0/57 (0.00%)” |
| Gastroesophageal reflux disease | “2/56 (3.57%)” | “2/54 (3.70%)” | “0/54 (0.00%)” | “0/57 (0.00%)” |
Single-night crossover: adverse events, withdrawals, and the serious adverse event, as described by the company
Four-week open-label extension: adverse events
Study limitations
Summary
- Publication status: results are available only from the registry record and the company prospectus.
- Design: four-period single-dose crossover with one-week washouts; participants who withdrew were not replaced, and 49 participants started the fourth period. The registry states the analysis did not analyze data by period and reported adverse events by treatment group only.
- Eligibility differs by source: the registry states AHI 10 to below 20, or 20 or more if other polysomnography criteria were met, while the prospectus states AHI 10 to 45 events/h with randomization limited to participants showing signs of low upper airway collapsibility. Ages were 25 to 65, and exclusions included a history of insomnia and clinically significant cardiac disease.
- Open-label extension: 37 of 60 participants received AD109 for 4 weeks without a control group; the reported reductions in hypoxic burden and AHI at week 4 and the SAQLI change versus baseline come from the prospectus.
- Withdrawals differ by source: the registry lists first-period non-completion as incorrectly randomized, lost to follow-up, and physician decision (1 each), while the prospectus states two participants withdrew because of adverse events (pleurisy and atrial fibrillation).
- Safety: one serious adverse event (possible seizure versus arrhythmia or atrial fibrillation) occurred with AD109 in a participant with a previously undisclosed history of arrhythmia and was considered unrelated to the drug.
- Sponsor: the prospectus describes APC-003 as a trial the company initiated.